DoctorChrissie Ong

Postdoctoral Research Fellow b

Menzies Institute for Medical Research

  • Postdoctoral Research Fellow b
    Menzies Institute for Medical Research

RESEARCH SUMMARy

Comparative immunology, tumour immunology, transmissible cancers, vaccines

FUNDED PROJECTS

  • GRANT
    Development of assays to detect immune responses in devils vaccinated against devil facial tumour disease
    1 Jun 2026 - 1 Jun 2028
    People funded by this grant:
    • Pye R,
    • Ong C,
    • Flies A,
    • Gonzalez Abarzua M,
    • Kruawan A
    Project Total: $75,000; Our group is developing a vaccine against devil facial tumour disease (DFTD). To determine the vaccines effectiveness, we need to develop assays to measure anti-DFTD immune responses induced in vaccinated devils. Results acquired from robust immunoassays are key to developing a vaccine that will best protect devils against DFTD. Funded by: University of Tasmania Foundation Inc - Internal Grant; University of Tasmania ($74,949).
  • GRANT
    DFTD vaccine safety and immunogenicity trials in marsupials
    1 Jun 2026 - 30 Jun 2028
    People funded by this grant:
    • Flies A,
    • Ong C,
    • Kruawan A,
    • Gonzalez Abarzua M,
    • Fisher M
    Project Total: $75,000; Background In 2019, our team launched an ambitious plan to develop an oral bait vaccine to prevent DFTD. By 2022, we had developed a candidate vaccine and begun testing field distribution methods. Unfortunately, our inexperience with regulatory permits and lack of vaccine manufacturing infrastructure led to extensive delays in vaccine trials. This project will trial DFT1 and DFT2 vaccines in fat-tailed dunnarts (Smithinopsis crassicaudata) in the existing UTAS animal services infrastructure to accelerate our work towards a registered vaccine for DFT1 and DFT2. Aims 1. Import dunnarts from mainland Australia and establish effective husbandry practices. 2. Trial DFT1 and DFT2 vaccine candidates in dunnarts Approach Dunnarts have been bred in captivity in Australia since at least the 1960s (Godfrey and Crowcroft, 1971; Scicluna et al., 2025). We have reserved a room in the UTAS Medical Sciences Precinct physical containment level 2 (PC2) animal facilities. This will allow us to control light-dark cycles and temperature to optimise conditions for dunnart husbandry. Members of our team and the animal services staff are travelling to our collaborators dunnart facility to learn husbandry techniques. Dunnarts will be allowed to acclimate to the new facility, and then will be allocated for either vaccine trials or breeding. The first trial will test our current DFT1 vaccine design, which encodes DFT1 targets into a human adenoviral vector (adenovector). An adenovector without DFT1 targets will be used as the negative control. Subsequent trials will test iteratively improved vaccine designs . Impact It has taken three years to get regulatory permits for our first vaccine trials with captive devils; testing several vaccine designs in dunnarts in PC2 facilities will greatly reduce the timelines for acquiring the necessary regulatory permits and allow us to acquire the data necessary for registration of a DFTD vaccine with the APVMA. Funded by: University of Tasmania Foundation Inc - Internal Grant; University of Tasmania ($75,000).
  • GRANT
    Harnessing alloreactive antibodies and T cells to develop a vaccine against transmissible cancers in Tasmanian devils
    1 Jun 2026 - 1 Jun 2028
    People funded by this grant:
    • Ong C,
    • Flies A,
    • Pye R,
    • Kruawan A,
    • Purcell A
    Project Total: $75,000; The Tasmanian devil (Sarcophilus harrisii) is the largest surviving carnivorous marsupial endemic to Tasmania, Australia. This iconic species is currently under threat from two independent transmissible cancers that cause the devil facial tumour disease (DFTD). Devil facial tumour (DFT) 1 and DFT2, are transmitted as allografts among devils through biting, typically killing the animal within 6-12 months of manifestation. Since the discovery of DFT1 in 1996, the wild devil population has experienced a steep decline of 82% in local densities. There are currently no viable treatments or prophylactics for DFTD; however, efforts are underway to create a vaccine to protect devils from this disease. Critical to vaccine success is the identification of targets that can induce long term protection against DFT1 and DFT2. Several studies have identified the major histocompatibility complex class I (MHC-I) molecules on DFT1 cells as the primary antibody target in devils with natural immunity to DFT1. MHC-I presents two mechanisms for DFT rejection, through (i) genetic mismatches between host MHC-I alleles and the six tumour MHC-I alleles, similar to an alloresponse in transplant rejection, and (ii) display of tumour-specific peptides on the peptide binding grooves of MHC-I. In this study, we aim to deconvolute the anti-MHC-I antibody response for vaccine development. Various recombinant MHC-I and peptide combinations will be generated to represent each tumour MHC-I allele with and without its unique set of peptides. Specific MHC-I allele(s) and/or MHC-I bound peptides that are recognized by devil serum antibodies will be tested in vitro for their ability to trigger devil T and B cell responses. The most immunogenic targets will be used to develop a vaccine against DFT1 and DFT2. Development of an effective vaccine will not only reduce disease transmission but more importantly, improve the welfare of devils and protect this endangered species from extinction Funded by: University of Tasmania Foundation Inc - Internal Grant; University of Tasmania ($74,946).
  • GRANT
    Cell line development and engineering to support a DFTD-resistant devil population
    1 Jan 2025 - 31 Dec 2026
    People funded by this grant:
    • Kruawan A,
    • Flies A,
    • Ong C
    Project Total: $59,700; Make new cell lines - this record contains a single grant application for Dr Eric Guiler Tasmanian Devil Research Grant and Dr Eric Guiler ACL Bearing Tasmanian Devil Early-career Research Grant. Budget from both grants are combined. Funded by: University of Tasmania Foundation Inc - Grant-Dr Eric Guiler Tasmanian Devil Research Gran; University of Tasmania ($59,700).
  • GRANT
    Development of a field ready DFT1/2 oral bait vaccine
    1 Jan 2024 - 31 Dec 2025
    People funded by this grant:
    • Flies A,
    • Pye R,
    • Ong C,
    • Croyle M,
    • Bunz F
    Project Total: $59,962; A vaccine that can limit the effects for DFT1 or eliminate DFT2 before it spreads across Tasmania has great potential to create a resilient wild devil population. This project will develop an experimental vaccine to target DFT1 and DFT2 and develop a formulation that stablises the vaccine in edible baits. Funded by: University of Tasmania Foundation Inc - Grant-Dr Eric Guiler Tasmanian Devil Research Gran; University of Tasmania ($59,962).
  • GRANT
    Production of specialised DFTD immunology tools to validate vaccine target antigens
    1 Jan 2024 - 31 Dec 2025
    People funded by this grant:
    • Flies A,
    • Ong C
    Project Total: $22,329; Our primary goal is to develop a protective vaccine against devil facial tumour disease (DFTD1,857). This project will develop reagents and tests to confirm the vaccine targets using the tissue bank of DFTD samples at Menzies. An effective DFTD vaccine will help rebuild the population of this Tasmanian icon. Funded by: University of Tasmania Foundation Inc - Grant-Dr Eric Guiler Tasmanian Devil Research Gran; University of Tasmania ($22,329).
  • GRANT
    Towards a better vaccine for DFTD: Characterisation of the immune correlates of protection
    1 Jan 2024 - 31 Dec 2025
    People funded by this grant:
    • Ong C,
    • Flies A,
    • Pye R,
    • Fairfax K
    Project Total: $49,853; Vaccines are a highly powerful and cost-effective tool to control disease in a population, particularly for infectious diseases. An effective vaccine for DFTD requires rational vaccine design that is guided by an understanding of the factors that confer protection. This project aims to investigate the mechanisms of protective anti-DFT immunity in both host and tumour using single cell RNA sequencing technology. This will help develop better therapeutic strategies to rebuild the wild devil population. Funded by: University of Tasmania Foundation Inc - Grant-Dr Eric Guiler Tasmanian Devil Research Gran; University of Tasmania ($49,853).
  • GRANT
    Uncovering MHC-I antigens in devil facial tumour cells for vaccine advancement
    1 Jan 2024 - 31 Dec 2025
    People funded by this grant:
    • Pye R,
    • Ong C,
    • Flies A,
    • Batley K
    Project Total: $45,385; Our groups primary goal is to develop a protective vaccine against devil facial tumour disease (DFTD). We will analyse blood from devils that have recovered from DFTD to identify the key components for a successful vaccine. A DFTD vaccine will contribute to rebuilding a resilient wild devil population. Funded by: University of Tasmania Foundation Inc - Grant-Dr Eric Guiler Tasmanian Devil Research Gran; University of Tasmania ($45,385).